Acelyrin to present 16-week data from Phase 2b/3 trial of izokibep

ACELYRIN announced that results from the company’s global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis will be shared as a late breaking oral presentation at the 2024 European Alliance of Associations for Rheumatology Congress taking place June 12-15 in Vienna, Austria. Izokibep is a small protein therapeutic designed to inhibit IL-17A, a validated mechanism for the treatment of PsA and other immune-mediated diseases. Presentation details are as follows: Title: Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 16 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2b/3 Study; Date/Time: Saturday, June 15, 2024; 9:30am – 9:40am CEST; Presenter: Philip Mease, MD, MACR, Director of Rheumatology Research at Swedish Medical Center The Phase 2b/3 clinical trial is a global, multi center, randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of izokibep dosed subcutaneously 160 mg every week or every two weeks and 80 mg every four weeks versus placebo. 351 adult patients with active PsA were enrolled across 71 sites in the United States and Europe and randomized across the four arms.